| Drug Name |
Fluvastatin sodium |
| Drug ID |
BADD_D00949 |
| Description |
Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class. Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. |
| Indications and Usage |
To be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
C10AA04 |
| DrugBank ID |
DB01095
|
| KEGG ID |
D00892
|
| MeSH ID |
D000077340
|
| PubChem ID |
23663976
|
| TTD Drug ID |
D08GHB
|
| NDC Product Code |
0781-8017; 0078-0354; 65727-012; 0527-2580; 14501-0009; 0093-7446; 48087-0093 |
| Synonyms |
Fluvastatin | Fluvastatin Sodium | Fluvastatin Sodium Salt | Fluindostatin | Lescol | XU 62-320 | XU 62 320 | XU-62320 | XU62320 | XU 62320 | 7-(3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate |
